Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Products under Development by Stage of Development | 8 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Products under Development by Therapy Area | 9 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Products under Development by Indication | 10 | 2 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Products under Development by Companies | 14 | 2 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Products under Development by Universities/Institutes | 16 | 2 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Therapeutics Assessment | 18 | 7 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 2 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Companies Involved in Therapeutics Development | 25 | 2 |
| D-Pharm Ltd. | 25 | 1 |
| Jazz Pharmaceuticals Plc | 26 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Drug Profiles | 27 | 19 |
| CT-140 Drug Profile | 27 | 1 |
| defibrotide sodium Drug Profile | 28 | 7 |
| Monoclonal Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke Drug Profile | 35 | 1 |
| Peptide to Activate PAI-1 for Acute Lung Injury Drug Profile | 36 | 1 |
| Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism Drug Profile | 37 | 1 |
| SK-216 Drug Profile | 38 | 1 |
| THR-18 Drug Profile | 39 | 3 |
| TM-5275 Drug Profile | 42 | 1 |
| TM-5441 Drug Profile | 43 | 1 |
| TM-5484 Drug Profile | 44 | 1 |
| TM-5509 Drug Profile | 45 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Dormant Projects | 46 | 3 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Discontinued Products | 49 | 1 |
| Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) Featured News &Press Releases | 50 | 12 |
| Aug 02, 2016: CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation | 50 | 1 |
| Mar 30, 2016: FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow | 50 | 1 |
| Mar 30, 2016: Jazz Pharmaceuticals Announces Webcast for Defitelio (defibrotide sodium) Investor Update | 51 | 1 |
| Feb 18, 2016: Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting | 51 | 2 |
| Feb 01, 2016: Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD | 53 | 1 |
| Sep 30, 2015: Jazz Pharmaceuticals Announces U.S. FDA Acceptance for Filing with Priority Review of NDA for Defibrotide for Hepatic Veno-Occlusive Disease | 54 | 1 |
| May 14, 2015: D-Pharm receives final report for its Phase 2 clinical study of THR-18 in acute stroke patients treated with tPA | 55 | 1 |
| Feb 12, 2015: Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease at BMT Tandem Meetings | 56 | 1 |
| Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA | 57 | 1 |
| Dec 11, 2014: Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease | 57 | 1 |
| Dec 02, 2014: Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting | 58 | 1 |
| Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA | 59 | 1 |
| Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA | 60 | 1 |
| Mar 31, 2014: Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease | 60 | 1 |
| Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients | 61 | 1 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |
